Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Bevacizumab + FOLFOX & Colorectal cancer (CRC), Bevacizumab + FOLFOX is a standard of care (SOC) for first-line treatment of Colorectal Cancer (CRC) (1)
In 2004, Bevacizumab was approved by the FDA for use alongside intravenous 5-FU-based chemotherapy as a first-line treatment for metastatic colorectal cancer. This includes the FOLFOX regimen, which is oxaliplatin-based and does not restrict based on Colorectal Cancer (CRC) (Mismatch Repair Deficiency (MMR-d) / DNA Mismatch Repair / Microsatellite Instability (MSI)) status. Therefore, it is…